Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Rhea-AI Summary

Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, will present updated data on seralutinib at the American Thoracic Society 2024 International Conference from May 17-22 in San Diego.

The presentations will include interim results from the Phase 1B and Phase 2 TORREY open-label extension study in pulmonary arterial hypertension (PAH) and additional data on circulating biomarkers, inflammation, and fibrosis. The main presentation will be on May 19 by Dr. Olivier Sitbon.

Positive

• Gossamer Bio will provide updated data on seralutinib, potentially enhancing investor confidence in its clinical pipeline.
• The presentation at a reputable conference like the American Thoracic Society 2024 may increase visibility and credibility of Gossamer Bio.
• Interim results from the Phase 1B and Phase 2 TORREY study will be highlighted, indicating ongoing research and potential progress.
• Additional data on circulating biomarkers, inflammation, and fibrosis could demonstrate the broader therapeutic impact of seralutinib.

Negative

• The press release does not disclose specific positive clinical outcomes, leaving uncertainty about the efficacy of seralutinib.
• The market may react unfavorably to the lack of new, concrete financial or clinical breakthroughs.

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:

Session: A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH
Session Date & Time: Sunday, May 19^th, 9:15 a.m. - 11:15 a.m. PT
Talk Title: Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Location: San Diego Convention Center, Room 29A-D (Upper Level)
Presenting Author: Olivier Sitbon, MD, PhD

Gossamer also will present additional data on seralutinib via poster. Details for those posters are as follows:

Poster Board Number: 424
Poster Session: D105 Balboa Park Explorers: Translational Science and Epidemiology in PH
Session Date & Time: Wednesday, May 22^nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment
Location: San Diego Convention Center, Room 25A-C (Upper Level)

Poster Board Number: 318
Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease
Session Date & Time: Wednesday, May 22^nd, 11:00 a.m. – 1:00 p.m. PT
Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Location: San Diego Convention Center, Room 28C-E (Upper Level)

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514616477/en/

For Investors and Media:

Bryan Giraudo, Chief Operating Officer and Chief Financial Officer

Gossamer Bio Investor Relations

ir@gossamerbio.com

Source: Gossamer Bio, Inc.

FAQ

When will Gossamer Bio present updated seralutinib data?

Gossamer Bio will present updated seralutinib data from May 17-22 at the American Thoracic Society 2024 International Conference in San Diego.

What is the focus of Gossamer Bio's presentation at the American Thoracic Society 2024?

Gossamer Bio will focus on presenting interim results from the Phase 1B and Phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension (PAH).

What is seralutinib?

Seralutinib is an inhaled PDGFR, CSF1R, and c-KIT inhibitor designed for the treatment of pulmonary hypertension.

Who will present the interim results of the TORREY study?

Dr. Olivier Sitbon will present the interim results of the TORREY study on May 19, 2024.